Peptide Intelligence · peptide
BPC-157
Also: Body Protection Compound 157, Pentadecapeptide BPC 157
A synthetic 15-amino-acid peptide derived from a protein found in gastric juice. Proposed to support tissue repair and gut lining, based mainly on animal studies.
Approval status
Not FDA-approved
Not FDA-approved for any use.
Compounding status
PCAC-recommended (Jul 2026) · rulemaking pending
Placed on FDA's Category 2 list (significant safety risk) in 2023. On Jul 23–24 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding it to the 503A bulks list. That vote is non-binding; rulemaking is pending, so nothing has changed legally yet. Research-use-only products are unapproved drugs with no quality assurance.
Evidence grade
C · Animal or in-vitro only
Animal and in-vitro studies; minimal human data.
If you already have a vial
Products sold as research-use-only are unapproved drugs. Nothing required the seller to verify identity, purity, sterility or concentration. That is the practical risk, more than the compound itself. Worth discussing with your clinician before you continue, and worth logging so your labs can be read against it.
Known risks and label warnings
- No human safety data at scale
- Unknown interactions
- Grey-market vials: contamination, mislabeling, incorrect concentration
Interactions people ask about
- Unknown
What people often measure
Framed as things to discuss with your clinician, not a protocol.
- Symptoms and any local injection-site reactions
- Baseline CMP, CBC and lipids are commonly measured before starting any injectable; discuss with your clinician
Questions for your clinician
- What would you want to see measured before and while I take this?
- How would we know if it is doing anything?
- How do I verify what is actually in the vial I bought?
Get the full report by email
- The BPC-157 status card, monitoring list and clinician questions, printable
- The pre-therapy baseline checklist: what people commonly measure before starting any injectable
- A note the next time FDA or HHS acts on this compound
Wellness guidance only, not medical advice. We never sell or dispense medication.
Regulatory timeline for BPC-157
2026-07-24
PCAC votes to recommend six peptides for the 503A bulks list
The Pharmacy Compounding Advisory Committee voted in favor of BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon. The votes are advisory only. Until FDA completes rulemaking, none of the six is legally compoundable and research-use-only products remain unapproved drugs.
FDA PCAC meeting page2026-04-15
Federal Register notice updates the peptide 'do not compound' list
FDA published an update to the Category 2 list and opened the process for nominated peptides to be evaluated for the 503A bulks list.
Frier Levitt analysis of the Apr 15 2026 notice2026-02-27
HHS announces a review of peptide compounding policy
HHS signaled it would revisit the compounding status of several peptides, setting up the April Federal Register notice and the July advisory-committee meeting.
Frier Levitt analysis2023-09-01
FDA places several wellness peptides on the Category 2 list
FDA's list of bulk drug substances that may present significant safety risks in compounding grew to include BPC-157, CJC-1295, ipamorelin, AOD-9604 and others. Category 2 substances cannot be used in 503A compounding.
FDA Category 2 page
Sources and review
- FDA PCAC meeting, Jul 23–24 2026
- AJMC: FDA panel backs 6 peptides for compounding
- Frier Levitt: FDA peptides 'do not compound' list update (Apr 15 2026 Federal Register)
Status as of 2026-09-02. Reviewed 2026-09-02 by Curtis Holder (product); clinical review pending; next review due 2026-11-01. Regulatory status changes; we update this page after each FDA or HHS action. Wellness guidance only, not medical advice. Med.xyz does not sell, prescribe or recommend any compound.